


The benefits of clinical research

March 2019

Economic benefits of commercial trials

- Australian sector worth \$1.1 billion; 1,360 trials; and 6,900 jobs (2015, LEK Consulting).
 - Includes direct trial costs, flow-on benefits, multiplier effects
- New Zealand sector generates \$384M in GDP per annum (Medicines NZ, 2017); 340 trials in 2015, (2018 HRC/MoH, ANZCTR).
 - Completeness of NZ data?

Case study: Hepatitis C



Case study: ICU network

- Albumin \$332/L vs saline \$1.60/L
 - Saline as safe (or safer than) standard of care
 - Saves \$137M per annum
- Tight blood sugar control is harmful for ICU patients
 - Not tightly controlling blood sugar levels is easier
 - Saves lives for an estimated 3% of ICU patients p/a globally
 - NZ has 20,000 patients p/a = 600 lives

Thanks to Colin McArthur for the information provided

Economic benefits of clinical trials

- Generate export revenues
- Avoid public healthcare costs
- Access to new medicines at no cost
- Productivity gains

New Zealand's advantages

- High-quality research facilities
- Efficient ethics and regulatory framework
- Can accommodate seasonal differences
- Diverse participant recruitment pool

from clinicaltrials.health.nz

New Zealand's challenges

- How do we stay competitive?
- Biggest risks in the commercial trials space?
- Biggest opportunities?
 - DHB engagement, ACC coverage, metadata/informatics, international outreach (BIO2019)
 - Therapeutic Products regulatory regime – friend or foe?
 - Patient pool, Regulatory environment, ethics, tax incentives